Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis

This open‐label disease‐drug–drug interaction study assessed whether blockade of the interleukin (IL)‐17A pathway by secukinumab and subsequent downregulation of inflammatory cytokines like IL‐6 or high‐sensitivity C‐reactive protein affects the pharmacokinetics (PKs) of a sensitive probe substrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruin, Gerard, Hasselberg, Anke, Koroleva, Irina, Milojevic, Julie, Calonder, Claudio, Soon, Rachel, Woessner, Ralph, Pariser, David M., Boutouyrie‐Dumont, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896234/
https://www.ncbi.nlm.nih.gov/pubmed/31228872
http://dx.doi.org/10.1002/cpt.1558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896234/
https://www.ncbi.nlm.nih.gov/pubmed/31228872
http://dx.doi.org/10.1002/cpt.1558

Ejemplares similares